Scholarlink

<p>Antenatal corticosteroids (ACS), most commonly administered as betamethasone or dexamethasone, remain a cornerstone of care for women at risk of preterm birth. However, the standard 24-mg regimen introduced more than five decades ago has not undergone formal dose-finding evaluation. Emerging concerns regarding possible dose-related adverse effects, particularly among late preterm infants subsequently born at term, have renewed interest in optimizing corticosteroid exposure. Experimental data across species, supported by human pharmacokinetic analyses, indicate that fetal lung maturation is driven by sustained low corticosteroid concentrations rather than high peak levels. This commentary summarizes key experimental, pharmacokinetic, and modelling evidence that informed the selection&#xa0;of the lower-dose betamethasone phosphate regimen evaluated in the WHO ACTION-III trial and explains the scientific rationale for this dosing strategy. Pharmacokinetic modeling indicates that 2&#xa0;mg betamethasone phosphate administered intramuscularly every 12&#xa0;h for four doses achieves fetal concentrations within the 1 to 4&#xa0;ng/mL range identified in experimental studies, while avoiding the supratherapeutic peaks observed with conventional regimens. The ACTION-III trial will evaluate whether this lower dose ACS regimen, chosen on the basis of carefully developed models and clinical studies, maintains clinical efficacy while potentially reducing unnecessary systemic corticosteroid exposure in women at risk of late preterm birth.</p><p><b>Trial registration</b>: ISRCTN11434567, registered on 7 June 2021.&#xa0;<a href="https://www.isrctn.com/ISRCTN11434567?q=ACTION-III&amp;filters=&amp;sort=&amp;offset=1&amp;totalResults=1&amp;page=1&amp;pageSize=10">https://www.isrctn.com/ISRCTN11434567?q=ACTION-III&amp;filters=&amp;sort=&amp;offset=1&amp;totalResults=1&amp;page=1&amp;pageSize=10</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) trial—rationale for the selected lower steroid dose

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月24日

查看全文
  • Ebunoluwa Aderonke Adejuyigbe,
  • Olubukola Adeponle Adesina,
  • Salahuddin Ahmed,
  • Shabina Ariff,
  • Adejumoke Idowu Ayede,
  • Rajiv Bahl,
  • Abdullah H. Baqui,
  • Harish Chellani,
  • Saleha Begum Chowdhury,
  • Ayesha De Costa,
  • Sangappa M. Dhaded,
  • Shivaprasad S. Goudar,
  • Shuchita Gupta,
  • Alan H. Jobe,
  • John Kinuthia,
  • Oluwafemi Kuti,
  • Tina Lavin,
  • Mark A. Milad,
  • Nicole Minckas,
  • My Huong Nguyen,
  • Olufemi T. Oladapo,
  • Yeshita V. Pujar,
  • Zahida P. Qureshi,
  • Suman P. N. Rao,
  • Mohammod Shahidullah,
  • Lumaan Sheikh,
  • Sajid Soofi,
  • Jyotsna Suri,
  • Joshua P. Vogel,
  • Nitya Wadhwa,
  • Fred Were

摘要

Antenatal corticosteroids (ACS), most commonly administered as betamethasone or dexamethasone, remain a cornerstone of care for women at risk of preterm birth. However, the standard 24-mg regimen introduced more than five decades ago has not undergone formal dose-finding evaluation. Emerging concerns regarding possible dose-related adverse effects, particularly among late preterm infants subsequently born at term, have renewed interest in optimizing corticosteroid exposure. Experimental data across species, supported by human pharmacokinetic analyses, indicate that fetal lung maturation is driven by sustained low corticosteroid concentrations rather than high peak levels. This commentary summarizes key experimental, pharmacokinetic, and modelling evidence that informed the selection of the lower-dose betamethasone phosphate regimen evaluated in the WHO ACTION-III trial and explains the scientific rationale for this dosing strategy. Pharmacokinetic modeling indicates that 2 mg betamethasone phosphate administered intramuscularly every 12 h for four doses achieves fetal concentrations within the 1 to 4 ng/mL range identified in experimental studies, while avoiding the supratherapeutic peaks observed with conventional regimens. The ACTION-III trial will evaluate whether this lower dose ACS regimen, chosen on the basis of carefully developed models and clinical studies, maintains clinical efficacy while potentially reducing unnecessary systemic corticosteroid exposure in women at risk of late preterm birth.

Trial registration: ISRCTN11434567, registered on 7 June 2021. https://www.isrctn.com/ISRCTN11434567?q=ACTION-III&filters=&sort=&offset=1&totalResults=1&page=1&pageSize=10.